Zobrazeno 1 - 10 of 65 pro vyhledávání: '"C. Ecoffet"'
1
Impact of psoriatic disease on women aged 18 to 45: Results from a multinational survey across 11 European countries
Autor: S.R. McBride, Marta García Bustínduy, Louise Catton, Maria Concetta Fargnoli, Laura Andreoli, Jan Koren, Laura C. Coates, Anne-Claire Fougerousse, Alice Titialii, Lerzan Senturk, C. Ecoffet
Publikováno v: International Journal of Women's Dermatology
International Journal of Women's Dermatology, Vol 7, Iss 5, Pp 697-707 (2021)
Background Plaque psoriasis (PSO) is a long-term inflammatory condition that can cause concomitant joint symptoms (psoriatic arthritis [PsA]) in up to 30% of patients. The impact of psoriatic disease on disease outcomes and quality of life is greater
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d3291c3c978522d66ef441c21b62860
http://europepmc.org/articles/PMC8714576
Zobrazit plný text záznamu
2
Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)
Autor: F Brock, Yves Poulin, Alice B. Gottlieb, Richard B. Warren, Andrew Blauvelt, M Boehnlein, C. Leonardi, Kenneth B. Gordon, Kristian Reich, Diamant Thaçi, C Ecoffet
Publikováno v: British Journal of Dermatology. 184:652-662
Background Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumour necrosis factor biologic. Objectives To report the 3-year efficacy of CZP in plaque psoriasis, pooled from the CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272) phase III tria
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8feba20f90b63ae993cf6c813f5c04b9
https://doi.org/10.1111/bjd.19393
Zobrazit plný text záznamu
3
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
Autor: Xavier Mariette, C. Ecoffet, Christopher Cioffi, Daniel E. Furst, Clifton O. Bingham, Désirée van der Heijde, Michael E. Weinblatt, B. VanLunen, Ronald F van Vollenhoven, Paul Emery, Gerd R Burmester, Vivian P. Bykerk
Publikováno v: Arthritis & Rheumatology (Hoboken, N.j.)
Arthritis & rheumatology (Hoboken, N.J.), 69(10), 1937-1948. John Wiley and Sons Ltd
Arthritis and Rheumatology, 69(10), 1937-1948. John Wiley and Sons Ltd
Arthritis and Rheumatology, 69(10), 1937-1948
Weinblatt, M E, Bingham, C O, Burmester, G R, Bykerk, V P, Furst, D E, Mariette, X, van der Heijde, D, van Vollenhoven, R, VanLunen, B, Ecoffet, C, Cioffi, C & Emery, P 2017, ' A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis ', Arthritis and Rheumatology, vol. 69, no. 10, pp. 1937-1948 . https://doi.org/10.1002/art.40196
Objective: In disease-modifying antirheumatic drug–naive patients with early rheumatoid arthritis (RA) who had achieved sustained low disease activity (a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate of ≤3.2 at both
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::273c8e454a0e5dda47c153461f403564
http://www.scopus.com/inward/record.url?scp=85031095929&partnerID=8YFLogxK
Zobrazit plný text záznamu
4
OP0331-HPR BARRIERS TO SHARED DECISION-MAKING WITH WOMEN OF REPRODUCTIVE AGE AFFECTED BY CHRONIC INFLAMMATORY DISEASES
Autor: Ivo Vlaev, M. Peniuta, D. Jenkins, Rebecca Fischer-Betz, C. Ecoffet, S. Murray, Catherine Nelson-Piercy, M. Augustyniak, Jenny E. Murase
Publikováno v: Annals of the Rheumatic Diseases. 79:203-203
Background:Previous research has indicated that women with a chronic inflammatory disease (CID) are likely to discontinue treatment during pregnancy. [1] Reasons for this are complex, including sub-optimal integration of shared decision-making (SDM)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b88cdd0ce24e2b0fa28126b1f14ca2d
https://doi.org/10.1136/annrheumdis-2020-eular.449
Zobrazit plný text záznamu
5
FRI0693 Fears and misconceptions of women with chronic rheumatic diseases on their journey to motherhood
Autor: Angela Tincani, E. Chakravarty, C. Ecoffet, Rebecca Fischer-Betz, P. Taylor
Publikováno v: FRIDAY, 15 JUNE 2018.
Background: Recent EULAR ‘Points to Consider’ provide guidance on management and treatment of Women of Childbearing Age (WoCBA) with chronic rheumatic diseases (CRD: RA, axSpA, PsA). However, it is still unclear if these patients (pts) feel adequ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d36fc9228bdad16c7fb6b155a852b7e8
https://doi.org/10.1136/annrheumdis-2018-eular.2063
Zobrazit plný text záznamu
6
FRI0692 Anti-tnf treatments for women with chronic inflammatory diseases: comparing attitudes and perceptions of physicians in europe and the us
Autor: P. Taylor, Rebecca Fischer-Betz, E. Chakravarty, Angela Tincani, C. Ecoffet
Publikováno v: FRIDAY, 15 JUNE 2018.
Background: For Women of Childbearing Age (WoCBA) with chronic inflammatory diseases (CID), onset, diagnosis and treatment initiation often overlap with peak reproductive years. High disease activity is associated with increased risk of pregnancy com
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ab7cce7b7b2130580159485c8d59367
https://doi.org/10.1136/annrheumdis-2018-eular.1919
Zobrazit plný text záznamu
7
THU0242 Pregnancy outcomes and disease activity in women with axial spondyloarthritis: a systematic literature review
Autor: Frauke Förger, Helena Marzo-Ortega, E. Thurtle, Megan E.B. Clowse, H.K. Resemann, Lianne S. Gensler, C. Ecoffet, D. Goff-Leggett, N. De Peyrecave, Stephanie A. Leonard, Anna Molto, A. Artignan
Publikováno v: THURSDAY, 14 JUNE 2018.
Background Women with axial spondyloarthritis (axSpA) are often affected by the disease during their reproductive years, 1 but reports on disease activity and pregnancy outcomes in these patients (pts) are sparse. In women with ankylosing spondylitis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::340ea66992c1bcf6835d4f9c7417a3e7
https://doi.org/10.1136/annrheumdis-2018-eular.3056
Zobrazit plný text záznamu
8
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
Autor: Gerd-Rüdiger Burmester, L. Gervitz, Josef S Smolen, Roy Fleischmann, Jeffrey R. Curtis, Lucian Ionescu, C. Ecoffet, Boulos Haraoui, Ronald F van Vollenhoven, Bernard Combe, Luke Peterson, Christopher Cioffi, Stephen Hall
Publikováno v: The Lancet
The Lancet, Elsevier, 2016, 388 (10061), pp.2763-2774. 〈10.1016/S0140-6736(16)31651-8〉
The Lancet, Elsevier, 2016, 388 (10061), pp.2763-2774. ⟨10.1016/S0140-6736(16)31651-8⟩
Lancet, 388(10061), 2763-2774. Elsevier Limited
Smolen, J S, Burmester, G-R, Combe, B, Curtis, J R, Hall, S, Haraoui, B, van Vollenhoven, R, Cioffi, C, Ecoffet, C, Gervitz, L, Ionescu, L, Peterson, L & Fleischmann, R 2016, ' Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis : 2-year efficacy and safety results from the randomised EXXELERATE study ', Lancet, vol. 388, no. 10061, pp. 2763-2774 . https://doi.org/10.1016/S0140-6736(16)31651-8
BACKGROUND: To date, head-to-head trials comparing the efficacy and safety of biological disease-modifying antirheumatic drugs within the same class, including TNF inhibitors, in patients with active rheumatoid arthritis despite methotrexate therapy
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0df90393d851c6dae45495a04e4c7459
https://hal.archives-ouvertes.fr/hal-01814961
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje